{"id":"NCT00789997","sponsor":"Ottawa Hospital Research Institute","briefTitle":"TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial","officialTitle":"TNF-alpha Antagonists for Acute Exacerbations of COPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2008-11","primaryCompletion":"2011-08","completion":"2011-10","firstPosted":"2008-11-13","resultsPosted":"2016-04-11","lastUpdate":"2016-04-11"},"enrollment":81,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["COPD Exacerbation"],"interventions":[{"type":"DRUG","name":"Prednisone","otherNames":[]},{"type":"DRUG","name":"Etanercept","otherNames":["Enbrel"]},{"type":"DRUG","name":"levofloxacin","otherNames":["levaquin"]}],"arms":[{"label":"Etanercept","type":"EXPERIMENTAL"},{"label":"Prednisone","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine whether treatment with antibiotics plus a TNFalpha antagonist will provide more effective treatment for acute COPD exacerbation compared to the current standard treatment of antibiotics plus prednisone.","primaryOutcome":{"measure":"Change in Lung Function (Forced Expiratory Volume in 1 Second (FEV1)","timeFrame":"Day 0 to Day 14","effectByArm":[{"arm":"Etanercept","deltaMin":15.2,"sd":5.7},{"arm":"Prednisone","deltaMin":20.1,"sd":5}],"pValues":[]},"eligibility":{"minAge":"35 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["23161645"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":41},"commonTop":["Leg Oedema","Achilles Tendonitis","Urinary Tract Infection","Sinusitis/pharyngitis","Pneumonia"]}}